Aerska is a biotechnology company focused on developing RNA interference (RNAi) medicines to treat neurological diseases. Leveraging its proprietary antibody-oligo conjugate (AOC) platform, Aerska aims to overcome the challenges of delivering genetic medicines across the blood-brain barrier. The company is advancing precision medicine strategies targeting genetic forms of Alzheimer's and Parkinson's diseases, with the goal of achieving durable gene silencing in the central nervous system (CNS). Headquartered in Dublin with research operations in London, Aerska is at the forefront of CNS therapeutics innovation.